These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Molecular design of a highly selective and strong protein inhibitor against matrix metalloproteinase-2 (MMP-2). Higashi S; Hirose T; Takeuchi T; Miyazaki K J Biol Chem; 2013 Mar; 288(13):9066-76. PubMed ID: 23395821 [TBL] [Abstract][Full Text] [Related]
26. Phosphoramidate-based peptidomimetic inhibitors of membrane type-1 matrix metalloproteinase. Mendes DE; Wong-On-Wing A; Berkman CE J Enzyme Inhib Med Chem; 2016; 31(1):167-71. PubMed ID: 25815671 [TBL] [Abstract][Full Text] [Related]
27. Engineered Peptide Macrocycles Can Inhibit Matrix Metalloproteinases with High Selectivity. Maola K; Wilbs J; Touati J; Sabisz M; Kong XD; Baumann A; Deyle K; Heinis C Angew Chem Int Ed Engl; 2019 Aug; 58(34):11801-11805. PubMed ID: 31251434 [TBL] [Abstract][Full Text] [Related]
28. Combinatorial engineering of N-TIMP2 variants that selectively inhibit MMP9 and MMP14 function in the cell. Arkadash V; Radisky ES; Papo N Oncotarget; 2018 Aug; 9(62):32036-32053. PubMed ID: 30174795 [TBL] [Abstract][Full Text] [Related]
29. Phage display of tissue inhibitor of metalloproteinases-2 (TIMP-2): identification of selective inhibitors of collagenase-1 (metalloproteinase 1 (MMP-1)). Bahudhanapati H; Zhang Y; Sidhu SS; Brew K J Biol Chem; 2011 Sep; 286(36):31761-70. PubMed ID: 21715326 [TBL] [Abstract][Full Text] [Related]
30. Structure-based design and optimization of pyrimidine- and 1,2,4-triazolo[4,3-a]pyrimidine-based matrix metalloproteinase-10/13 inhibitors via Dimroth rearrangement towards targeted polypharmacology. El Ashry ESH; Awad LF; Teleb M; Ibrahim NA; Abu-Serie MM; Abd Al Moaty MN Bioorg Chem; 2020 Mar; 96():103616. PubMed ID: 32032847 [TBL] [Abstract][Full Text] [Related]
31. N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity. Nuti E; Cantelmo AR; Gallo C; Bruno A; Bassani B; Camodeca C; Tuccinardi T; Vera L; Orlandini E; Nencetti S; Stura EA; Martinelli A; Dive V; Albini A; Rossello A J Med Chem; 2015 Sep; 58(18):7224-40. PubMed ID: 26263024 [TBL] [Abstract][Full Text] [Related]
32. Multiple receptor-ligand based pharmacophore modeling and molecular docking to screen the selective inhibitors of matrix metalloproteinase-9 from natural products. Gao Q; Wang Y; Hou J; Yao Q; Zhang J J Comput Aided Mol Des; 2017 Jul; 31(7):625-641. PubMed ID: 28623487 [TBL] [Abstract][Full Text] [Related]
33. Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays. Adhikari N; Halder AK; Mallick S; Saha A; Saha KD; Jha T Bioorg Med Chem; 2016 Sep; 24(18):4291-4309. PubMed ID: 27452283 [TBL] [Abstract][Full Text] [Related]
34. TIMP2 deficiency accelerates adverse post-myocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation. Kandalam V; Basu R; Abraham T; Wang X; Soloway PD; Jaworski DM; Oudit GY; Kassiri Z Circ Res; 2010 Mar; 106(4):796-808. PubMed ID: 20056917 [TBL] [Abstract][Full Text] [Related]
35. Identification of small molecule inhibitors against MMP-14 via High-Throughput screening. Lee H; Youn I; Demissie R; Vaid TM; Che CT; Azar DT; Han KY Bioorg Med Chem; 2023 May; 85():117289. PubMed ID: 37094433 [TBL] [Abstract][Full Text] [Related]
36. Mutational study of the amino-terminal domain of human tissue inhibitor of metalloproteinases 1 (TIMP-1) locates an inhibitory region for matrix metalloproteinases. Huang W; Meng Q; Suzuki K; Nagase H; Brew K J Biol Chem; 1997 Aug; 272(35):22086-91. PubMed ID: 9268350 [TBL] [Abstract][Full Text] [Related]